We are live on
!
Find out more
Lyell Immunopharma
LYEL
LYEL
77 hedge funds and large institutions have $662M invested in Lyell Immunopharma in 2021 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 27 increasing their positions, 11 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
145% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 11
136% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 11
24% more funds holding
Funds holding: 62 → 77 (+15)
0.05% more ownership
Funds ownership: 1.72% → 1.78% (+0.05%)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
46% less capital invested
Capital invested by funds: $1.22B → $662M (-$559M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $148K
Holders
77
Holders Change
+15
Holders Change %
+24.19%
% of All Funds
1.18%
Holding in Top 10
4
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-33.33%
% of All Funds
0.06%
New
26
Increased
27
Reduced
11
Closed
11
Calls
–
Puts
$148K
Net Calls
-$148K
Net Calls Change
-$148K
Top Buyers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$16.5M |
| 2 |
E
Ergoteles
New York
|
+$11.2M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$7.62M |
| 4 |
BlackRock
New York
|
+$6.38M |
| 5 |
AP
Adero Partners
Pleasanton,
California
|
+$5.48M |
